Galectin Therapeutics
GALT
93 hedge funds and large institutions have $12.2M invested in Galectin Therapeutics in 2025 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 30 reducing their positions, and 12 closing their positions.
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
0.21% less ownership
Funds ownership: 16.2% → 15.99% (-0.21%)
1% less funds holding
Funds holding: 94 → 93 (-1)
6% less capital invested
Capital invested by funds: $13M → $12.2M (-$805K)
40% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 30
71% less call options, than puts
Call options by funds: $757K | Put options by funds: $2.57M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$330K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$173K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$77K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$77K |
| 5 |
LPL Financial
San Diego,
California
|
+$76.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$332K |
| 2 |
CCB
Cutter & Co Brokerage
Ballwin,
Missouri
|
-$149K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$104K |
| 4 |
Barclays
London,
United Kingdom
|
-$63.6K |
| 5 |
Morgan Stanley
New York
|
-$63.1K |
GALT Hedge Fund Activity: Q1 2025 in Review
93 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2025, worth a combined $12.2M — down 6.2% from $13M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new GALT positions and 12 closed out — a net gain of 1 holder — while 18 added to existing stakes and 30 trimmed.
The largest buyer was Y-Intercept (HK), opening a new position worth an estimated $330K. The largest seller was BlackRock, cutting an estimated $332K.
- 93 institutional investors held Galectin Therapeutics (GALT) as of Q1 2025, down from 94 in Q4 2024.
- Funds reported $12.2M of Galectin Therapeutics stock for Q1 2025, down 6.2% quarter-over-quarter.
- 13 funds opened new Galectin Therapeutics positions in Q1 2025 and 12 closed out, a net change of +1 holder.
- The largest Galectin Therapeutics buyer in Q1 2025 was Y-Intercept (HK), an estimated $330K added.
- The largest Galectin Therapeutics seller in Q1 2025 was BlackRock, an estimated $332K sold.
Based on aggregated 13F filings for Q1 2025.